Biological Factors – Page 3

Key Presentations at JPM25: AbbVie, UCB, WuXi Biologics Highlight Industry Trends

7 months ago talkbio0Tagged AbbVie, Biological Factors, biotech, healthcare innovation, J.P. Morgan Healthcare, JPM25, trends qualifier, UCB, WuXi

JPM25, J.P. Morgan Healthcare Conference, AbbVie, UCB, WuXi Biologics, Biotech Trends, Healthcare Innovation

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion to Strengthen Neuroscience Portfolio

7 months ago talkbio0Tagged Acquisition, Biological Factors, Caplyta, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, Neuroscience discipline

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, CAPLYTA, Lumateperone, Biopharmaceutical

WuXi Biologics Divests Irish Vaccine Facility to Merck for $500 Million Amid Strategic Shift

8 months ago talkbio0Tagged asset, Biological Factors, BIOSECURE, Dundalk, Facility (object), Ireland, Merck, regulatory, Sales - occupational activity, strategic shift, Vaccines, WuXi

WuXi Biologics, Merck, vaccine manufacturing facility, Dundalk, Ireland, asset sale, strategic shift, regulatory changes, Biosecure Act

Merck Acquires WuXi Biologics’ Irish Vaccine Facility in $500M Deal

8 months ago talkbio0Tagged Biological Factors, Facility (object), Ireland, Merck, pharmaceutical manufacturing, Vaccines, WuXi

Merck, WuXi Biologics, vaccine facility, Ireland, $500M deal, pharmaceutical manufacturing

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Advance Development of Atopic Dermatitis Treatment

8 months ago talkbio0Tagged Biological Factors, Clinical stage finding, Dermatitis, Atopic, Ikena Oncology, IMG-007, Implantation procedure, Inmagene Biopharmaceuticals, Merger, Monoclonal Antibodies, Private Room, TNFRSF4 gene

Ikena Oncology, Inmagene Biopharmaceuticals, Merger, Atopic Dermatitis, IMG-007, Monoclonal Antibody, OX40, Biopharmaceuticals, Clinical Stage, Private Placement

Strategic Roadmap for Biologics Manufacturing: Enhancing Efficiency and Flexibility

9 months ago talkbio0Tagged Biological Factors, biomanufacturing, bony process, Characterization, Continuous, Efficiency, Manufacturing, Modular Facilities, Pliability, Precision medicines, Regulatory Compliance, Strategic Roadmap, technology roadmap

Biologics manufacturing, Strategic roadmap, Process characterization, Flexibility and efficiency, Regulatory compliance, Biomanufacturing technology roadmap, Precision medicines, Modular facilities, Continuous manufacturing

Biocon Biologics Secures FDA Approval for YESINTEK, a Biosimilar to Stelara

9 months ago talkbio0Tagged Approved, Biocon, Biological Factors, Inflammatory disorder, Stelara biosimilar, United States Food and Drug Administration, ustekinumab, YESINTEK

Biocon Biologics, FDA approval, YESINTEK, Stelara biosimilar, ustekinumab, inflammatory diseases

Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Private Equity Deal

10 months ago talkbio0Tagged Avid, Biological Factors, Bioservices, Capital Partners, CDMO, GHO, Private Equity

Avid Bioservices, GHO Capital Partners, Ampersand Capital Partners, biologics CDMO, private equity acquisition, $1.1 billion deal

AbbVie and EvolveImmune Therapeutics Collaborate on Next-Generation Cancer Biotherapeutics Using T-Cell Engager Technology

10 months ago talkbio0Tagged AbbVie, Biological Factors, EvolveImmune, Immunotherapy, Next-Generation Cancer, Oncology Collaboration, T-Cell Engager Technology, Tumor cells, malignant

AbbVie, EvolveImmune Therapeutics, T-Cell Engager Technology, Next-Generation Cancer Biotherapeutics, Oncology Collaboration, Multispecific Biologics, Cancer Cell Resistance, Immunotherapies

Ocuphire Pharma Acquires Opus Genetics, Expanding into Inherited Retinal Disease Gene Therapies

10 months ago talkbio0Tagged Acquisition, Biological Factors, gene therapy, Hereditary, IRDs, Ocuphire Pharma, ophthalmic treatments, Opus, Retinal Diseases, Science of genetics

Ocuphire Pharma, Opus Genetics, gene therapy, inherited retinal diseases (IRDs), merger, acquisition, biopharmaceutical, ophthalmic treatments